← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kineta, Inc.
Seattle, WA
$20,755,785
Total funding
12
Grants
Funding over time
peak $2.8M · FY2008–23$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$20,755,785 · 12
By mechanism
R01$8,376,017 · 2
R44$5,751,548 · 3
N01$4,768,493 · 2
R43$1,634,750 · 4
R41$224,977 · 1
Investigators at Kineta, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,417,922
N01 · FY2015 · AI
Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever$1,370,459
R01 · FY2019 · AI
Antiviral Drugs for Arenaviruses$1,296,933
R01 · FY2015 · AI
Antiviral Drugs for Arenaviruses$1,228,837
R01 · FY2014 · AI
Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever$1,163,830
R01 · FY2020 · AI
Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever$1,134,275
R01 · FY2021 · AI
Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever$1,118,000
R01 · FY2022 · AI
Animal Models as Surrogates, SBIR Phase I ^ RFP No. PHS 2010-1 Topic #13$1,087,851
N01 · FY2011 · HL
Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever$1,063,683
R01 · FY2023 · AI
Agonists of the RIG-I Innate Immune Pathway$992,047
R44 · FY2011 · AI
Agonists of the RIG-I Innate Immune Pathway$956,404
R44 · FY2012 · AI
Agonists of the RIG-I Innate Immune Pathway$798,935
R44 · FY2013 · AI
Development of novel isoflavone drugs as broad spectrum antivirals$757,817
R44 · FY2016 · AI
Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics$750,000
R44 · FY2020 · CA
Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics$750,000
R44 · FY2019 · CA
Development of novel isoflavone drugs as broad spectrum antivirals$746,345
R44 · FY2017 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$641,709
N01 · FY2016 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$641,708
N01 · FY2016 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$499,380
N01 · FY2016 · AI
Development of Kv1.3 channel blocker ShK-186 as a therapy for multiple sclerosis$300,000
R43 · FY2011 · AI